404

Not Found

Is this what you were looking for?

modules lib modules linktrack php
By Lloyd Dunlap

Taking the fifth

PDUFA legislation is reauthorized by House and Senate for fifth time since 1992
By Amy Swinderman

Forming a pharma fund

Index Ventures, GSK and J&J align to make $240 million in venture-capital funding available to life-science companies with early-stage assets
By Jeffrey Bouley

Making trials less of a trial

Janssen Research & Development announces establishment of databank to enhance global cross-pharmaceutical clinical trial efforts
By Jeffrey Bouley

Ariadne’s thread of connections

Bioinformatics company to collaborate in multimillion-dollar EU-based neuromuscular disease consortium to find biomarkers
By Arthur J. Hiller, SciFluor

Finding the right balance

If you’ve ever met with a financial planner or investment advisor, then you know that one of the first rules of investing is diversification, an important risk management technique that ensures there are a variety of assets within a portfolio. As biopharmaceutical organizations, it is important that we recognize the dire consequences that may result if we ignore this proven strategy.

Run a Search

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue